ZheJiangTailin Bioengineering Co Ltd
SZSE:300813
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (189.2), the stock would be worth ¥14.68 (41% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 320.3 | ¥24.85 |
0%
|
| 3-Year Average | 189.2 | ¥14.68 |
-41%
|
| 5-Year Average | 58.3 | ¥4.52 |
-82%
|
| Industry Average | 26.8 | ¥2.08 |
-92%
|
| Country Average | 28.8 | ¥2.24 |
-91%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
ZheJiangTailin Bioengineering Co Ltd
SZSE:300813
|
3B CNY | 320.3 | 182.7 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 226.4 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
176.7B USD | 18.4 | 26.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
125.4B USD | 17.6 | 34 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 30.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 16.3 | 15.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 16.1 | -118.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 18.6 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.4B USD | 30.5 | 47.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.5B USD | 11.5 | 20.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.1B USD | 22.3 | 30 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
ZheJiangTailin Bioengineering Co Ltd
Glance View
Zhejiang Tailin Bioengineering Co., Ltd. engages in the research, development, manufacturing, and sales of pharmaceutical equipment, including microbial detection and control technology system products, as well as organic substance analysis instruments. The company is headquartered in Hangzhou, Zhejiang and currently employs 869 full-time employees. The company went IPO on 2020-01-14. The firm's main business is the research, development, manufacturing and sales of microbial detection and control technology system products, organic substance analysis instruments and other pharmaceutical equipment. Specific products include various consumables, instruments and equipment, which can be used alone or in combination for the production and quality of sterile drugs. The application areas that can be expanded include medical and health, food safety, disease prevention and control, biosecurity, inspection and quarantine, biological engineering, laboratory animals, and environmental protection. The firm distributes its products within domestic market and to overseas markets.
